Try our Advanced Search for more refined results

Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc.

  1. January 04, 2019

    Full Fed. Circ. Won't Revisit 'Blocking Patent' Ruling

    The Federal Circuit on Friday said it wouldn't reconsider the invalidation of four patents covering Acorda Therapeutics Inc.'s flagship multiple sclerosis drug Ampyra, despite the drugmaker's argument that the decision had "radically expand[ed]" the so-called blocking patent doctrine.

  2. November 28, 2018

    Full Fed. Circ. Asked To Skip 'Blocking Patent' Case

    Generics makers Roxane and Teva urged the full Federal Circuit Tuesday not to rehear a decision invalidating four Acorda patents on the multiple sclerosis drug Ampyra, arguing that the ruling was a careful application of the so-called blocking patent doctrine, not an expansion of it.

  3. October 25, 2018

    Full Fed. Circ. Urged To Rehear 'Blocking Patents' Ruling

    Acorda Therapeutics Inc. urged the full Federal Circuit on Wednesday to reconsider an earlier ruling invalidating several patents covering its flagship multiple sclerosis drug Ampyra, arguing that the decision "radically expands" the so-called blocking patent doctrine and may hinder pharmaceutical innovation.

  4. September 18, 2018

    Fed. Circ. Ruling Takes 'Blocking Patents' To New Places

    The Federal Circuit's recent ruling invalidating patents on Acorda Therapeutics Inc.'s multiple sclerosis drug Ampyra could expand the impact of so-called blocking patents and may make it easier to show an invention is obvious, attorneys say.

  5. September 10, 2018

    Fed. Circ. Backs Decision Axing 4 Acorda MS Drug Patents

    A split Federal Circuit panel on Monday upheld a judge's decision that four patents on Acorda Therapeutics Inc.'s multiple sclerosis drug Ampyra are invalid as obvious, clearing the way for competing generic versions and putting the drug's over $500 million in annual sales in jeopardy.

  6. June 07, 2018

    Blocking Patent Focus Of Acorda's Fed. Circ. MS Drug Appeal

    Acorda urged a Federal Circuit panel Thursday to revive four patents covering its flagship product, the multiple sclerosis drug Ampyra, in oral arguments focusing heavily on whether a "blocking patent" held by another company was sufficient to deem Acorda's patents invalid due to obviousness.

  7. August 10, 2017

    Acorda Asks Fed. Circ. To Undo Nix Of Ampyra Drug Patents

    Acorda on Wednesday kicked off its arguments challenging a Delaware federal judge's invalidation of the asserted claims of patents covering its blockbuster multiple sclerosis drug Ampyra, contending that the judge erred in concluding that they were obvious.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!